Enhertu demonstrated statistically significant improvement in invasive DFS vs. T-DM1 in DESTINY-Breast05 Ph III trial in patients with high-risk early breast cancer following neoadjuvant therapy September 30, 2025
Pivotal Ziftomenib Data in R/R NPM1-Mutated AML Published in the Journal of Clinical Oncology September 30, 2025
ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable pancreatic cancer patients in Ph 2 AMPLIFY-7P Trial September 23, 2025
Extended Survival Achieved in Low PD-L1 Cohort in VERSATILE-002 Trial of PDS0101 (Versamune® HPV) + Keytruda in patients with HPV16-positive 1L R/M HNSCC September 23, 2025
100% MRD negativity seen in Ph 2 MajesTEC-5 study of TECVAYLI & DARZALEX FASPRO induction in transplant-eligible 1L multiple myeloma September 23, 2025
LP-184 Ph 1a Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors September 23, 2025
New Ph 2 Data for Stenoparib/2X-121 Showed Landmark Median OS Surpassing 25 Months September 23, 2025
IMNN-001 Ph 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift September 23, 2025
Positive Ph 3 Results Show Giredestrant Significantly Improved PFS in ER-Positive Advanced Breast Cancer September 23, 2025
Ph 1/2a Plixorafenib Data Demonstrated Prolonged Duration of Effect in BRAF Altered Thyroid Cancers September 23, 2025
Positive Interim Efficacy Analysis of Ph 2 Trial of ENV105 in Advanced Prostate Cancer with Median PFS of Over One Year Announced September 23, 2025
Patients With Aggressive Brain and Advanced Liver Cancers Treated with PIC monotherapy Reach Five Years of Durable RFS September 23, 2025
Final results from OPTIMIZE-1 trial of mitazalimab – mFOLFIRINOX combo in 1L metastatic pancreatic cancer patients announced September 23, 2025
PADCEV™ + KEYTRUDA™ combo Significantly Improves Survival before and after SOC (surgical cystectomy) in cisplatin-ineligible MIBC patients September 16, 2025
Asia cohort of Ph 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) + LAZCLUZE® (lazertinib) achieved statistically significant OS improvement vs osimertinib in EGFRm NSCLC September 16, 2025
Plixorafenib demonstrated mPFS of 64 months and a CBR of 85.7% in patients with MAPKi-naïve BRAF V600-mutated papillary thyroid cancer September 16, 2025
Rezatapopt Monotherapy Interim Data From PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced September 16, 2025
WCLC 2025: Final Analysis of Firmonertinib Monotherapy Data from Ph 1b Study in EGFR PACC Mutant NSCLC presented September 16, 2025
WCLC 2025: Libtayo + chemo demonstrates a more than double 5yr OS rate of 19.4% vs 8.8% with chemo alone in NSCLC September 16, 2025
WCLC 2025: Cadonilimab – Pulocimab Combo Shows Promising Results in IO-Resistant NSCLC September 16, 2025
WCLC 2025: Updated efficacy and safety data presented from Ph 2b REZILIENT1 trial of zipalertinib in EGFRm, amivantamab-ref NSCLC patients September 16, 2025
Positive efficacy data announced from Ph 2 trial of THIO-101 & cemiplimab (Libtayo®) in NSCLC patients who had failed two or more SoC therapy regimens September 16, 2025
